VPC-70619
Based on 2 publication(s) in Google Scholar
VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.93%
- CAS No.: 2361742-30-3
- 화학식: C16H8ClF3N4O
- 분자량:364.71
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-122683
sAJM589Myc Inhibitor -
HY-124675
MYCMI-6MYC:MAX Interaction Inhibitor -
HY-129600
MYCi361c-Myc Inhibitor -
HY-12702
10058-F4c-Myc Inhibitor -
HY-134761
EN4Covalent Ligand of c-MYC -
HY-100669
Mycro 3Myc-Max Inhibitor -
HY-145898
WBC100c-Myc Inhibitor -
HY-103618
THZ531CDK12/13 Inhibitor -
HY-134975
NY2267Myc-Max Interaction Disruptor -
HY-162318
MYC degrader 1MYC Degrader -
HY-121418
Lusianthridinc-Myc Inhibitor -
HY-124129
10074-A4c-Myc Inhibitor
Publications Citing Use of MedChemExpress (MCE) VPC-70619
More
Biological Activity
제품 설명
In Vitro
VPC-70619 (10 μM) exhibits an inhibition rate of 99.4% in IMR32 cells, while only 14.1% in HO15.19 cells[1].
VPC-70619 (1-10 μM) is shown to be highly stable with a T1/2 of 2310 min in In liver microsomes[1].
VPC-70619 upregulates the mRNA levels of MYCN, MDM2, and CRABP2, and downregulates TGM2 and INHBA, confirming its specific regulatory effect on the MYCN signaling pathway in SW1736-PTX and 8505C-PTX cells[2].
VPC-70619 (0.5-30 μM, 0-72 h) inhibits the proliferation, migration and aggressiveness of SW1736-PTX and 8505C-PTX cells, and the effect is enhanced when combined with Paclitaxel[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
Chemical Information
-
CAS No. 2361742-30-3
-
Appearance Solid
-
분자량 364.71
-
화학식 C16H8ClF3N4O
-
Color Off-white to light yellow
-
SMILES
N#CC1=CC(C(F)(F)F)=C(C=C1)NNC(C2=CC=C(C(Cl)=C2)C#N)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation. [Abstract]2023 Mar 22;24(6):5993. PMID: 36983070 -
용액&용해도
In Vitro:
DMSO : ≥ 100 mg/mL (274.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ton AT, et al. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. Int J Mol Sci. 2022;23(5):2588. Published 2022 Feb 26. [Content Brief]
[2]. Molteni E, et al. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation. Int J Mol Sci. 2023 Mar 22;24(6):5993. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7419 mL | 13.7095 mL | 27.4190 mL | 68.5476 mL |
| 5 mM | 0.5484 mL | 2.7419 mL | 5.4838 mL | 13.7095 mL | |
| 10 mM | 0.2742 mL | 1.3710 mL | 2.7419 mL | 6.8548 mL | |
| 15 mM | 0.1828 mL | 0.9140 mL | 1.8279 mL | 4.5698 mL | |
| 20 mM | 0.1371 mL | 0.6855 mL | 1.3710 mL | 3.4274 mL | |
| 25 mM | 0.1097 mL | 0.5484 mL | 1.0968 mL | 2.7419 mL | |
| 30 mM | 0.0914 mL | 0.4570 mL | 0.9140 mL | 2.2849 mL | |
| 40 mM | 0.0685 mL | 0.3427 mL | 0.6855 mL | 1.7137 mL | |
| 50 mM | 0.0548 mL | 0.2742 mL | 0.5484 mL | 1.3710 mL | |
| 60 mM | 0.0457 mL | 0.2285 mL | 0.4570 mL | 1.1425 mL | |
| 80 mM | 0.0343 mL | 0.1714 mL | 0.3427 mL | 0.8568 mL | |
| 100 mM | 0.0274 mL | 0.1371 mL | 0.2742 mL | 0.6855 mL |
VPC-70619 Related Classifications
HY-144878 Related Classifications
Powered by Bioz